Hood River Capital Management LLC lifted its stake in MacroGenics, Inc. (NASDAQ:MGNX) by 2.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 588,799 shares of the biopharmaceutical company’s stock after acquiring an additional 12,606 shares during the period. Hood River Capital Management LLC owned 1.60% of MacroGenics worth $10,881,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of MacroGenics by 6.0% in the 2nd quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock worth $91,733,000 after acquiring an additional 295,553 shares in the last quarter. BB Biotech AG raised its position in shares of MacroGenics by 4.0% in the 2nd quarter. BB Biotech AG now owns 2,350,112 shares of the biopharmaceutical company’s stock worth $41,150,000 after acquiring an additional 90,112 shares in the last quarter. Vanguard Group Inc. raised its position in shares of MacroGenics by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,391,322 shares of the biopharmaceutical company’s stock worth $24,362,000 after acquiring an additional 38,458 shares in the last quarter. Wasatch Advisors Inc. raised its position in shares of MacroGenics by 5,159.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock worth $18,285,000 after acquiring an additional 1,024,388 shares in the last quarter. Finally, State Street Corp raised its position in shares of MacroGenics by 20.0% in the 1st quarter. State Street Corp now owns 1,007,211 shares of the biopharmaceutical company’s stock worth $18,732,000 after acquiring an additional 167,720 shares in the last quarter. 84.72% of the stock is owned by hedge funds and other institutional investors.
MGNX has been the topic of several research analyst reports. Stifel Nicolaus restated a “buy” rating and set a $34.00 target price on shares of MacroGenics in a research note on Tuesday, September 12th. Zacks Investment Research downgraded MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Cowen and Company restated a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. SunTrust Banks, Inc. restated a “buy” rating and set a $26.00 target price on shares of MacroGenics in a research note on Friday, September 1st. Finally, ValuEngine upgraded MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $30.10.
TRADEMARK VIOLATION WARNING: “Hood River Capital Management LLC Buys 12,606 Shares of MacroGenics, Inc. (MGNX)” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/17/hood-river-capital-management-llc-buys-12606-shares-of-macrogenics-inc-mgnx.html.
MacroGenics, Inc. (NASDAQ:MGNX) traded up $0.19 during trading on Friday, reaching $18.18. The company’s stock had a trading volume of 262,200 shares, compared to its average volume of 261,266. MacroGenics, Inc. has a twelve month low of $14.36 and a twelve month high of $29.48.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The firm’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.97) EPS. equities research analysts forecast that MacroGenics, Inc. will post -0.7 earnings per share for the current year.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.